Thus, combinatorial targeting of MEK inhibitors (trametinib, cobimetinib, binimetinib) with RAF inhibitors (vemurafenib, dabrafenib, encorafenib) has been FDA-approved, from 2014 to 2018, for patients with metastatic melanoma, non-small cell lung cancer (NSCLC), and anaplastic thyroid cancer carrying the BRAF V600E mutation [72,73,92,93,94]. Here, RAF1 is linked to non-small cell lung carcinoma.